Tosoh Bioscience Ltd Launches the Latest Edition to its Range of HPLC Analyzers at Focus 2012

03 May 2012
Share
Tosoh Bioscience Ltd. launched its new automated glycohaemoglobin analyser at the Association of Clinical Biochemistry’s National Focus 2012 meeting, in Liverpool, this week. The Tosoh GX has been adapted specifically to handle low volume HbA1c requirements.

Diabetes mellitus (DM) is a group of diseases characterised by a disrupted carbohydrate metabolism. Insufficient production or functioning of the pancreatic hormone insulin, leads to elevated blood glucose levels (hyperglycaemia), and secretion of glucose in the urine (glycosuria).

Glycated haemoglobin (HbA1c) levels are used as a measure of average plasma glucose concentration over prolonged periods of time. Poor patient control correlates with increased HbA1c levels. It is estimated that by the year 2030, the total number of diabetics worldwide will reach 366 million. Such epidemic proportions mean that the measurement of HbA1c represents a significant workload challenge to many laboratories.

The GX analyser utilises the same technology as the company’s existing high-throughput G8 analyser, but has been designed so that it can be used by both laboratory staff and healthcare professionals in low volume laboratories or clinic environments. The analyser offers high precision and enables direct determination of stable HbA1c with less than 1% CV, it also shows excellent correlation with the G8 analyser. The system is easy to use with fully automated maintenance and easy result interpretation. Stable HbA1c results with variant detection are available in 2.2 minutes; time to the first result is 6.6 minutes.

For more information on the GX analyser or any others in the Tosoh range, please follow the company website link below.

Request Info


Company website

Tosoh Bioscience GmbH
profile photo

Sonia Nicholas
Clinical Diagnostics Editor